DelistingMay 22, 2026, 04:18 PM
XTL Biopharmaceuticals Receives Nasdaq Delist Determination
AI Summary
XTL Biopharmaceuticals announced it received a delist determination from Nasdaq due to its failure to timely file its Annual Report on Form 20-F for the year ended December 31, 2025. This adds to existing non-compliance issues regarding minimum stockholders' equity and bid price requirements, for which the company is already before a Nasdaq Hearings Panel. The Panel will consider this new deficiency, and XTL intends to request an extended stay of the suspension of its securities from The Nasdaq Capital Market by May 26, 2026.
Key Highlights
- XTL Biopharmaceuticals received a Nasdaq delist determination for not filing its 2025 Annual Report on Form 20-F.
- This non-compliance with Listing Rule 5250(c)(1) is an additional basis for delisting.
- The company is already before a Nasdaq Hearings Panel for failing to meet the minimum $2.5 million stockholders' equity rule (5550(b)(1)).
- XTL also failed to comply with the minimum $1 bid price requirement (Rule 5550(a)(2)).
- The Nasdaq Hearings Panel will consider this new deficiency in its decision.
- XTL has until May 26, 2026, to present its views and request a stay of suspension of its securities.
- The company intends to request an extended stay of the suspension.
Price Impact
More from XTLB